首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1791428篇
  免费   142102篇
  国内免费   3094篇
耳鼻咽喉   24217篇
儿科学   58678篇
妇产科学   51232篇
基础医学   255269篇
口腔科学   53712篇
临床医学   153299篇
内科学   356579篇
皮肤病学   40069篇
神经病学   145712篇
特种医学   69504篇
外国民族医学   501篇
外科学   266322篇
综合类   40657篇
现状与发展   3篇
一般理论   584篇
预防医学   144534篇
眼科学   41086篇
药学   135717篇
  2篇
中国医学   3632篇
肿瘤学   95315篇
  2018年   20342篇
  2017年   15176篇
  2016年   16553篇
  2015年   19028篇
  2014年   25775篇
  2013年   38822篇
  2012年   54382篇
  2011年   57043篇
  2010年   32877篇
  2009年   30692篇
  2008年   53042篇
  2007年   55920篇
  2006年   56302篇
  2005年   54712篇
  2004年   53276篇
  2003年   50620篇
  2002年   49444篇
  2001年   80634篇
  2000年   83705篇
  1999年   70730篇
  1998年   18963篇
  1997年   17199篇
  1996年   17123篇
  1995年   16759篇
  1994年   15646篇
  1993年   14761篇
  1992年   57801篇
  1991年   56031篇
  1990年   54822篇
  1989年   52814篇
  1988年   49129篇
  1987年   48310篇
  1986年   46027篇
  1985年   44520篇
  1984年   33254篇
  1983年   28670篇
  1982年   16781篇
  1981年   14985篇
  1979年   31844篇
  1978年   22011篇
  1977年   18639篇
  1976年   17502篇
  1975年   18591篇
  1974年   22786篇
  1973年   21963篇
  1972年   20073篇
  1971年   18946篇
  1970年   17409篇
  1969年   16442篇
  1968年   15119篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic nephroma, were among the first solid tumours shown to harbour recurrent tyrosine kinase fusions, with the canonical ETV6::NTRK3 fusion identified more than 20 years ago. Although targeted testing has long been used in diagnosis, the advent of more robust sequencing techniques has driven the discovery of kinase alterations in an array of mesenchymal tumours. As our ability to identify these genetic alterations has improved, as has our recognition and understanding of the tumours that harbour these alterations. Specifically, this study will focus upon mesenchymal tumours harbouring NTRK or other kinase alterations, including tumours with an infantile fibrosarcoma-like appearance, spindle cell tumours resembling lipofibromatosis or peripheral nerve sheath tumours and those occurring in adults with a fibrosarcoma-like appearance. As publications describing the histology of these tumours increase so, too, do the variety kinase alterations reported, now including NTRK1/2/3, RET, MET, RAF1, BRAF, ALK, EGFR and ABL1 fusions or alterations. To date, these tumours appear locally aggressive and rarely metastatic, without a clear link between traditional features used in histological grading (e.g. mitotic activity, necrosis) and outcome. However, most of these tumours are amenable to new targeted therapies, making their recognition of both diagnostic and therapeutic import. The goal of this study is to review the clinicopathological features of tumours with NTRK and other tyrosine kinase alterations, discuss the most common differential diagnoses and provide recommendations for molecular confirmation with associated treatment implications.  相似文献   
2.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
3.
4.
5.
6.
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass.  相似文献   
7.
8.
9.
10.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号